Resale prospectus for 6.82M shares from April private placement sparks heavy premarket selling pressure.
On April 29, 2026, Enveric filed a Form 424B3 prospectus registering approximately 6.82 million shares of common stock for resale by selling stockholders. These shares consist of those issued in the mid-April $13.9 million (upfront ~$5M) private placement priced at $2.25 per share/unit, plus shares underlying pre-funded warrants, Series I and J warrants, and placement agent warrants. The filing creates immediate share overhang, as investors who participated in the discounted raise (well below recent trading levels near $5) can now sell freely once effective. This overhang weighed on sentiment after the stock’s sharp recent rally driven by patent grants for its EVM301/EB-003 program and sector momentum around psychedelics policy. The registration directly explains the rapid -24%+ premarket move on April 30 as traders priced in potential supply and dilution risk. No other company-specific negative catalysts (earnings, clinical setbacks, or regulatory actions) were reported in the immediate timeframe.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.